Dopamine D2 Receptor and Dopamine Transporter mRNA Expression in Addicted Peripheral Blood Lymphocytes

Document Type : Original Article

Authors

1 Student Research Committee, Qom University of Medical Sciences, Qom, Iran

2 Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

3 Isfahan University of Medical Sciences, Isfahan, Iran

4 Neurosciences Research Center, Qom University of Medical Sciences, Qom, Iran

5 Spiritual Health Research Center, Qom University of Medical Sciences, Qom, Iran

10.34172/ahj.1714

Abstract

Introduction: This study aimed to detect the effects of opioid addiction on the mRNA expression levels of the dopamine D2 receptor (DRD2) and dopamine transporter (DAT) in peripheral blood leukocytes.
Methods: Four groups, each comprising 30 individuals, were included in the study: opioid-addicted, methadone-maintained (MM), long-term abstinent, and normal subjects. We measured the mRNA levels of DRD2 and DAT in peripheral blood leukocytes via real-time quantitative reverse transcription‒polymerase chain reaction (real-time RT‒PCR).
Findings: The results of the study showed that DAT mRNA expression was not statistically significant in the affected subjects compared to the control group. Regarding DRD2, mRNA expression was increased significantly in the MM subjects compared to the control group (P = 0.002).
Conclusion: Our study could guide further research to refine the clinical applicability of biomarkers related to dopamine signaling proteins in opioid addiction.

Highlights

Sadegh Yoosefee(Google Scholar)(Pubmed)

Keywords

References

  1. Vassoler FM, Sadri-Vakili G. Mechanisms of transgenerational inheritance of addictive-like behaviors. Neuroscience 2014;264:198-206. doi:10.1016/j.neuroscience.2013.07.064
  2. Kreek MJ, Nielsen DA, LaForge KS. Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromolecular Med 2004;5(1):85-108. doi:10.1385/ nmm:5:1:085
  3. Yang L, Zhang L, Zhang H, Liu J. Application of omics-based biomarkers in substance use disorders. Meta Radiol 2023;1(1):100008. doi:10.1016/j.metrad.2023.100008
  4. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9(6):557-69. doi:10.1038/sj.mp.4001507
  5. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998;80(1):1-27. doi:10.1152/jn.1998.80.1.1
  6. Mash DC, Pablo J, Ouyang Q, Hearn WL, Izenwasser S. Dopamine transport function is elevated in cocaine users. J Neurochem 2002;81(2):292-300. doi:10.1046/j.1471- 4159.2002.00820.x
  7. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, et al. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 2001;117(1-2):133-42. doi:10.1016/s0165-5728(01)00317-4
  8. Jabeen S, Pinsonneault JK, Sadee W, Lee SH, Zafar MM, Raja MS, et al. Significant association of DRD2 enhancer variant rs12364283 with heroin addiction in a Pakistani population. Ann Hum Genet 2019;83(5):367-72. doi:10.1111/ahg.12322
  9. Qin Y, Sun Q, Wang L, Hu F, Zhang Q, Wang W, et al. DRD2 TaqIA polymorphism-related functional connectivity between anterior insula and dorsolateral prefrontal cortex predicts the retention time in heroin-dependent individuals under methadone maintenance treatment. Eur Arch Psychiatry Clin Neurosci 2024;274(2):433-43. doi:10.1007/s00406-023- 01626-6
  10. Kirillova GP, Hrutkay RJ, Shurin MR, Shurin GV, Tourkova IL, Vanyukov MM. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods 2008;174(2):272-80. doi:10.1016/j. jneumeth.2008.07.018
  11. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002;132(1-2):34-40. doi:10.1016/s0165- 5728(02)00280-1
  12. Goodarzi A, Vousooghi N, Sedaghati M, Mokri A, Zarrindast MR. Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. Eur J Pharmacol 2009;615(1-3):218-22. doi:10.1016/j.ejphar.2009.04.060
  13. Buttarelli FR, Fanciulli A, Pellicano C, Pontieri FE. The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. Curr Neuropharmacol 2011;9(2):278-88. doi:10.2174/157015911795596612
  14. Nazari S, Pourmand SM, Makki SM, Brand S, Vousooghi N. Potential biomarkers of addiction identified by real-time PCR in human peripheral blood lymphocytes: a narrative review. Biomark Med 2022;16(9):739-58. doi:10.2217/ bmm-2021-0291
  15. Volkow ND, Wiers CE, Shokri-Kojori E, Tomasi D, Wang GJ, Baler R. Neurochemical and metabolic effects of acute and chronic alcohol in the human brain: studies with positron emission tomography. Neuropharmacology 2017;122:175- 88. doi:10.1016/j.neuropharm.2017.01.012
  16. 16. Liu L, Yuan G, Cheng Z, Zhang G, Liu X, Zhang H. Identification of the mRNA expression status of the dopamine D2 receptor and dopamine transporter in peripheral blood lymphocytes of schizophrenia patients. PLoS One 2013;8(9):e75259. doi:10.1371/journal.pone.0075259
  17. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: APA; 2013.
  18. Gardner EL, Ashby CR Jr. Heterogeneity of the mesotelencephalic dopamine fibers: physiology and pharmacology. Neurosci Biobehav Rev 2000;24(1):115-8. doi:10.1016/s0149-7634(99)00048-2
  19. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend 1998;51(1-2):13-22. doi:10.1016/s0376- 8716(98)00063-5
  20. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000;24(1):125- 32. doi:10.1016/s0149-7634(99)00063-9
  21. Koob GF, Caine SB, Hyytia P, Markou A, Parsons LH, Roberts AJ, et al. In: Glantz MD, Hartel CE, eds. Neurobiology of drug addiction. In: Drug abuse: Origins & Interventions. American Psychological Association; 1999. p. 161-90. doi:10.1037/10341-008
  22. Czermak C, Lehofer M, Wagner EM, Prietl B, Gorkiewicz G, Lemonis L, et al. Reduced dopamine D3 receptor expression in blood lymphocytes of smokers is negatively correlated with daily number of smoked cigarettes: a peripheral correlate of dopaminergic alterations in smokers. Nicotine Tob Res 2004;6(1):49-54. doi:10.1080/14622200310001656858
  23. Mill J, Asherson P, Browes C, D’Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3’ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002;114(8):975-9. doi:10.1002/ajmg.b.10948
  24. Robbins TW, Everitt BJ. Drug addiction: bad habits add up. Nature 1999;398(6728):567-70. doi:10.1038/19208
  25. Bonci A, Williams JT. Increased probability of GABA release during withdrawal from morphine. J Neurosci 1997;17(2):796- 803. doi:10.1523/jneurosci.17-02-00796.1997
  26. Madhavan A, Bonci A, Whistler JL. Opioid-induced GABA potentiation after chronic morphine attenuates the rewarding effects of opioids in the ventral tegmental area. J Neurosci  2010;30(42):14029-35. doi:10.1523/jneurosci.3366-10.2010
  1. Manzoni OJ, Williams JT. Presynaptic regulation of glutamate release in the ventral tegmental area during morphine withdrawal. J Neurosci 1999;19(15):6629-36. doi:10.1523/ jneurosci.19-15-06629.1999
  2. Melis M, Spiga S, Diana M. The dopamine hypothesis of drug addiction: hypodopaminergic state. Int Rev Neurobiol 2005;63:101-54. doi:10.1016/s0074-7742(05)63005-x
  3. Tang F, Yang L, Yang W, Li C, Zhang J, Liu J. The genetic susceptibility analysis of TAAR1 rs8192620 to methamphetamine and heroin abuse and its role in impulsivity. Eur Arch Psychiatry Clin Neurosci 2024;274(2):453-9. doi:10.1007/s00406-023-01613-x
  4. Alonso IP, Pino JA, Kortagere S, Torres GE, España RA. Dopamine transporter function fluctuates across sleep/wake state: potential impact for addiction. Neuropsychopharmacology 2021;46(4):699-708. doi:10.1038/s41386-020-00879-2
  5. Georges F, Stinus L, Bloch B, Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur J Neurosci 1999;11(2):481- 90. doi:10.1046/j.1460-9568.1999.00462.x
  6. Sánchez-Cardoso P, Higuera-Matas A, Martín S, Miguéns M, Del Olmo N, García-Lecumberri C, et al. Strain differences between Lewis and Fischer 344 rats in the modulation of dopaminergic receptors after morphine self-administration and during extinction. Neuropharmacology 2009;57(1):8-17. doi:10.1016/j.neuropharm.2009.03.014
  7. Smith SS, O’Hara BF, Persico AM, Gorelick DA, Newlin DB, Vlahov D, et al. Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Arch Gen Psychiatry 1992;49(9):723-7. doi:10.1001/ archpsyc.1992.01820090051009
  8. Noble EP, Blum K, Khalsa ME, Ritchie T, Montgomery A, Wood RC, et al. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug Alcohol Depend 1993;33(3):271-85. doi:10.1016/0376-8716(93)90113-5
  9. Persico AM, Bird G, Gabbay FH, Uhl GR. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 1996;40(8):776-84. doi:10.1016/0006-3223(95)00483-1
  10. Comings DE, Muhleman D, Ahn C, Gysin R, Flanagan SD. The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend 1994;34(3):175-80. doi:10.1016/0376-8716(94)90154-6
  11. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;6(1):73-9. doi:10.1097/00008571-199602000-00006
  12. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002;23(2):93-105. doi:10.1016/s0740- 5472(02)00259-3
  13. Shippenberg TS, Herz A. Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol 1988;151(2):233-42. doi:10.1016/0014- 2999(88)90803-5
  14. Shippenberg TS, Zapata A, Chefer VI. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 2007;116(2):306-21. doi:10.1016/j.pharmthera.2007.06.011
  15. Bondy B, Ackenheil M, Birzle W, Elbers R, Fröhler M. Catecholamines and their receptors in blood: evidence for alterations in schizophrenia. Biol Psychiatry 1984;19(10):1377-93.
  16. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry 1999;46(10):1388-95. doi:10.1016/S0006- 3223(99)00117-1
  17. Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson’s disease. Neurology 1996;46(3):791-5. doi:10.1212/wnl.46.3.791
Addiction & Health
Volume 18
Pages 1-6

Files

Share

How to cite

Statistics